Introduction {#s01}
============

Obesity is a major epidemic in the first world ([@bib28]; [@bib52]) and is considered to be a leading cause for proinflammatory metabolic syndrome, cancer development, and increased mortality ([@bib31]; [@bib6]; [@bib32]). Among its numerous physiological consequences, obesity affects bone marrow (BM) homeostasis. A high-fat diet (HFD) qualitatively and quantitatively modifies the composition of the adipocyte tissue in the BM while disrupting the ability of mesenchymal progenitors to generate osteoblastic cells ([@bib41]; [@bib66]; [@bib19]). In addition to its local effects, obesity is associated with profound systemic dysregulations. Adipose tissue acts as an active endocrine organ that secretes a plethora of bioactive substances ([@bib37]). As a consequence, obesity contributes to adipokine and hormone imbalance. In parallel, obesity triggers the infiltration of activated immune cells into the adipose tissue, leading to a chronic inflammatory phenotype. Altogether, obesity can be considered as a chronic and complex pathological state associated with systemic and BM-specific stresses.

Previous studies have demonstrated the effect of diet and obesity on the hematopoietic system ([@bib22]; [@bib70]; [@bib2]; [@bib48]). Conditions associated with metabolic dysregulations such as adipose tissue accumulation, hyperglycemia, and hypercholesterolemia have been linked to hematopoietic disruption and particularly to myeloid skewing ([@bib49], [@bib50]; [@bib2]; [@bib69]). Recent research studying the direct effect of obesity on the hematopoietic stem and progenitor cells (HSPCs) specifically focused on the signals induced by the obese inflammatory state ([@bib63], [@bib64]; [@bib71]). Other dysregulations in HSPC compartments were associated with disruptions in the BM microenvironment. Research identified the expansion of the BM adipocytes as a key limiting factor of the hematopoietic activity upon transplantation ([@bib51]). Similarly, diabetes has been shown to affect the mobilization capacity of hematopoietic stem cells (HSCs) by altering chemokine expression in the BM niche ([@bib27]). Finally, a study has linked diet-induced modification of the microbiota to alteration of the BM endosteal niche and hematopoietic dysregulation ([@bib46]). Although they describe specific effects of obesity on the hematopoietic system, these studies do not address its long-term effect on the fitness of the HSC compartment, the HSC-specific regulatory mechanisms that are disrupted in this condition, or whether these effects can persist upon weight loss.

The HSC compartment is highly heterogeneous, being composed of multiple cell subsets with variable levels of quiescence, self-renewal capability, and potential for differentiation ([@bib75]; [@bib17]; [@bib12]; [@bib76]). Contribution of these various HSC subsets to steady-state and emergency hematopoiesis is still a matter of debate ([@bib68]; [@bib14]; [@bib62]). However, maintenance of a healthy HSC pool is essential to sustaining a normal long-term hematopoiesis. Pathophysiological conditions such as aging, which are associated with a restriction of the diversity of the HSC compartment and the accumulation of myeloid-biased HSCs, correlate with hematopoietic disruptions and an increased susceptibility to hematological malignancies ([@bib3]). Although obesity has also been associated with hematological pathologies ([@bib13]), its impact on the global fitness of the HSC compartment remains poorly understood. In this study, we show that obesity alters the cellular architecture of the HSC compartment and modifies its functional properties in response to acute hematopoietic stresses. We show that obesity has a progressive effect on the HSC compartment but also that some of the acquired properties in these conditions can persist upon weight loss or exposure to a normal environment. Molecularly, we establish that the transcription factor Gfi1 is a key regulator of the HSC fate in obesity by controlling its quiescence status and contributing to its aberrant stress response. Finally, we establish the role of the chronic oxidative stress in regulating *Gfi1* expression in HSCs. Altogether, this work identifies key cellular and molecular mechanisms by which obesity, viewed as a chronic stress, affects the HSC compartment and could promote durable disruption of its fitness.

Results {#s02}
=======

Obesity modifies the composition of the HSC compartment {#s03}
-------------------------------------------------------

Obesity is a complex and multicausal condition. To fully recapitulate its phenotype, we conducted our studies in two different mouse models of obesity ([@bib47]). First, we used a genetic obese mouse model (hereafter denoted as *db* mice) carrying an inactivating mutation in the leptin receptor (*Lepr*) gene ([@bib21]). Leptin is an adipokine secreted by adipocytes, which is part of a negative feedback loop that modulates fat tissue by regulating appetite and energy expenditure. Inactivation of the leptin signaling in the central nervous system induces hyperphagia, leading to rapid and homogeneous weight gain ([Fig. 1 A](#fig1){ref-type="fig"}). We analyzed *db* mice at 16 wk of age to allow for the interaction of adult HSCs with the environment of established obesity. To validate our results, we used a dietary mouse model in which WT mice are fed with HFD ([@bib39]). Mice in this model take up to 5 mo to achieve significant weight gain ([Fig. 1 A](#fig1){ref-type="fig"}). As such, we performed our analyses on 8-mo-old HFD-fed WT mice with the potential caveat of adding age as a confounding parameter ([@bib77]). At these time points, obese *db* and HFD-fed mice showed reduced BM cellularity associated with the accumulation of adipocytes in the BM ([Figs. 1 B](#fig1){ref-type="fig"} and S1 A). Consistent with previous research on the *db* model, we observed that obesity correlated with myeloid--lymphoid imbalance in steady-state hematopoiesis ([@bib50]), with (A) significant reduction of the B cell progenitor populations ([@bib22]; [@bib1]) and (B) skewing of the myeloid-committed progenitor compartment (lineage^--^/c-Kit^+^/Sca-1^--^; LK) toward the granulocyte--macrophage progenitors (GMPs) at the expense of the megakaryocyte--erythroid progenitors (unpublished data; [@bib50]). Of note, these results appear milder than previously reported in the HFD model (unpublished data; [@bib46]), suggesting that environmental factors might modulate the immune phenotype of this model.

![**HSCs maintain a highly quiescent state in obesity.** (**A**) Kinetics of weight gain in genetic (*db*) and dietary (HFD) mouse models of obesity. *db*, *n* = 5; HFD, *n* = 8. **(B)** BM cellularity of 4-mo-old *db* mice compared with *Ctrl* littermates. *n* = 13/group. Images show H&E staining of the BM section from *Ctrl* and *db* mice (*n* = 3). Arrowheads indicate BM adipocytes. Bars, 100 µm. **(C)** FACS plots of HSPC populations in the BM of 4-mo-old *Ctrl* and *db* mice (*n* = 6). Right panels show strategies used to position CD34^--^ and CD49b^--^ gates. **(D)** Mean percentages (left) and absolute numbers (right) ± SD of HSPC populations in the BM of 4-mo-old *Ctrl* and *db* mice. *n* = 13/group. **(E and F)** Phenotypic definition and mean percentages ± SD of HSC subsets in the BM of 4-mo-old *Ctrl* and *db* mice. *n* = 6/group. **(G)** Representative FACS plots (left) and mean percentages ± SD (right) of *Ctrl* and *db* SLAM HSC distribution in cell cycle phases. *n* = 4/group. Two independent experiments. **(H)** qRT-PCR analyses for *Cdkn1a*, *Cdkn1b*, and *Cdkn1c* gene expression in SLAM HSCs isolated from 4-mo-old *db* mice. Results are expressed as fold change ± SD relative to *Ctrl* SLAM HSCs. *n* = 12 pools of 100 cells. Student's *t* test; \*, P ≤ 0.05; \*\*, P ≤ 0.005; \*\*\*, P ≤ 0.0005. Two independent experiments.](JEM_20170690_Fig1){#fig1}

We then analyzed the BM immature lineage^--^/c-Kit^+^/Sca-1^+^ (LSK) compartment, subfractionated based on the expression of the signaling lymphocyte activation molecules (SLAM), CD150 and CD48 ([Fig. 1 C](#fig1){ref-type="fig"}; [@bib40]). In *db* mice, we noticed a slight expansion of the LSK compartment caused by the increase of the short-term LSK CD48^+^ CD150^+/−^ multipotent progenitors (MPPs; [Fig. 1 D](#fig1){ref-type="fig"}). This increase was found in all myeloid and lymphoid-biased MPP subpopulations (known as MPP2/3 and MPP4, respectively), suggesting that obesity did not affect the differentiation pathways within the MPP compartments (not depicted; [@bib55]). In contrast with MPPs, the frequency of the LSK CD48^−^CD150^+^ SLAM HSCs was not significantly affected in obese mice. Overall, the absolute number of SLAM HSCs and MPPs remained unchanged in *db* mice despite the overall loss of BM cellularity ([Fig. 1 D](#fig1){ref-type="fig"}). Interestingly, detailed analyses based on the CD34 and CD49b markers revealed changes in the cellular subsets that compose the *db* SLAM HSC compartment ([Fig. 1, E and F](#fig1){ref-type="fig"}). First, we observed in *db* mice the expansion of the CD34^--^LSK CD48^−^CD150^+^ compartment that contains the most quiescent and self-renewing HSC population as opposed to the more cycling and short-term CD34^+^LSK CD48^−^CD150^+^ compartment (known as MPP1; [Fig. 1 C](#fig1){ref-type="fig"}; [@bib75]). We then used the CD49b marker, which was previously shown to define intermediate-term HSC potential within the CD34^--^HSC compartment ([@bib73]; [@bib75]; [@bib11]; [@bib56]). In obesity, we found the specific expansion of the intermediary CD49b^+^CD34^--^HSC (HSC^CD49b+^) population, suggesting that a dysregulation of the differentiation process occurs at the transition between the quiescent HSC (HSC^CD49b-^) and the active MPP1 compartments ([Fig. 1, C and F](#fig1){ref-type="fig"}). Importantly, the relevance of these HSC subsets defined by the CD34 and CD49b markers was highlighted by gene expression analyses. Notably, phenotypically defined HSC^CD49b--^ expressed high levels of the transcription factors *Mecom* and *Ndn*, which are involved in the regulation of HSC quiescence and self-renewal (Fig. S2 A; [@bib7], [@bib8]; [@bib38]). Conversely, MPP1 cells expressed high levels of *Myc,* a key regulator of HSC differentiation (Fig. S2 A; [@bib74]). HSC^CD49b+^ showed an intermediary phenotype for these molecular features compatible with its position in the SLAM HSC compartment. Overall, the expression levels of *Mecom*, *Ndn*, and *Myc* in the HSC subsets were consistent with previous studies comparing SLAM HSC subpopulations (Fig. S2 B; [@bib15], [@bib16]) but were not significantly affected in obesity (Fig. S2 A). In contrast, obesity was associated with an increased quiescence of the overall SLAM HSC compartment as indicated by intracellular Hoechst/pyronin Y staining ([Fig. 1 G](#fig1){ref-type="fig"}) and an increase in the percentage of side population LSK cells with high dye efflux capacity (not depicted; [@bib30]; [@bib5]). These changes in quiescence status were consistent with the modification in the cellular structure of the SLAM HSC compartment in obesity and particularly with the expansion of the CD34^--^ fraction. In addition, in vitro tracking of cell division kinetics suggests that obesity could also affect the intrinsic properties of these subsets. As expected, these assays showed different division kinetics between HSC subsets (Fig. S2 C, left). They also uncovered that obesity promotes a slight delay (∼4 h) in the onset of the first division of the MPP1 cells, compatible with an increased quiescence of this subset (Fig. S2 C, right). Finally, increased quiescence in the whole SLAM HSC compartment was correlated with a specific up-regulation of *Cdkn1a,* a cyclin-dependent kinase inhibitor previously shown to regulate HSC stress response ([Fig. 1 H](#fig1){ref-type="fig"}; [@bib20]; [@bib72]).

The BM LSK compartment in the dietary mouse model recapitulated some of the phenotypic characteristics found in the *db* model. Notably, we observed a significant expansion of the MPP compartment in HFD-fed mice (Fig. S1, B and C). However, consistent with their age (8 mo), SLAM HSCs showed increased frequency and higher CD150 expression in both chow diet (CD)- and HFD-fed mice ([@bib60]; [@bib10]). We also observed an expansion of the CD34^--^ SLAM HSC population in both conditions, a phenotype precluding the analysis of the HSC subsets defined by the CD49b marker (Fig. S1 D; [@bib10]). Altogether, our results recapitulate previous studies that describe the effects of obesity on hematopoietic lymphoid- and myeloid-committed progenitors ([@bib1]; [@bib50]). These analyses indicate that obesity does not dramatically change the overall size of the SLAM HSC compartment. However, in the genetic model, obesity is associated with changes in the cellular structure and the functional properties of this compartment that together lead to an overall increased quiescence.

Obesity promotes an aberrant HSC response to stress {#s04}
---------------------------------------------------

To explore the functional consequences of these changes in vivo, we performed competitive transplantation assays using purified SLAM HSCs isolated from *Ctrl* or *db* mice ([Fig. 2 A](#fig2){ref-type="fig"}). Analysis of the peripheral blood (PB) showed a dramatically increased chimerism in recipient mice transplanted with *db* SLAM HSCs ([Fig. 2 B](#fig2){ref-type="fig"}, left). Engraftment was stable over a 5-mo period with myeloid and lymphoid cell production indistinguishable from the controls ([Fig. 2 B](#fig2){ref-type="fig"}, middle). BM analyses at 5 mo after transplantation did not reveal any major differences between groups, notwithstanding an increase of chimerism in the *db* MPP compartment that mimicked the phenotype observed in primary obese mice ([Fig. 2 B](#fig2){ref-type="fig"}, right). Donor-derived *db* SLAM HSCs used for secondary competitive transplantation showed sustained but dramatically reduced reconstitution ability ([Fig. 2 C](#fig2){ref-type="fig"}, left). Analyses at 5 mo after transplantation showed reduced chimerism in all BM hematopoietic compartments with the exception of the SLAM HSC compartment, which displayed a high degree of chimerism similar to controls ([Fig. 2 C](#fig2){ref-type="fig"}, right). At this time point, *Ctrl* and *db* SLAM HSCs displayed similar high CD150 levels (not depicted) and similar skewing toward the production of myeloid cells (*Ctrl*, 67.3 ± 8.2%, versus *db,* 68.4 ± 10.4%; [Fig. 2 C](#fig2){ref-type="fig"}, middle; [@bib10]). Similar but milder results were obtained with the 8-mo-old dietary mouse model (Fig. S3 A). Similar to the *db* condition, SLAM HSCs isolated from HFD-fed mice displayed a hyperactive phenotype in primary transplantations and enhanced MPP production (Fig. S3 B). In contrast, no differences were observed in secondary transplantations as CD and HFD SLAM HSCs showed similar low engraftment (Fig. S3 C). Altogether, these results demonstrate that obesity affects the ability of HSCs to respond to the hematopoietic stresses associated with transplantation. These results show that obesity drives an aberrant biphasic HSC stress response that includes enhanced reconstitution ability in primary recipients and functional exhaustion after serial transplantation. Collectively, these results demonstrate that obesity triggers cell-intrinsic mechanisms that affect the long-term fitness of the HSC compartment.

![**Functional impact of obesity on HSCs. (A)** Experimental scheme for serial transplantation assay. **(B and C)** Hematopoietic reconstitution in primary and secondary recipients. The left graph indicates PB chimerism over time. The middle graph shows myeloid and lymphoid PB chimerism 20 wk after transplantation. The right graph shows the percentage of donor-derived total BM cells, SLAM HSCs, MPPs, and myeloid progenitors (MPs) 20 wk after transplantation. Results are expressed as means ± SEM. *n* = 8 and 4. Student's *t* test; \*, P ≤ 0.05; \*\*, P ≤ 0.01. Four and two independent experiments, respectively.](JEM_20170690_Fig2){#fig2}

Obesity is associated with up-regulation of *Gfi1* expression in HSCs {#s05}
---------------------------------------------------------------------

We next investigated the molecular mechanisms that could contribute to the abnormal function of the HSC compartment in obesity. We performed genomewide gene expression analysis on 20,000 SLAM HSCs isolated from 4-mo-old *Ctrl* and *db* mice ([Fig. 3 A](#fig3){ref-type="fig"} and Table S3). Gene set enrichment analyses (GSEAs) indicated a specific down-regulation in the obesity of genes associated with metabolic processes (e.g., mitochondrion and generation of metabolite precursor and energy), a set of functions potentially related to their increased quiescent status ([Fig. 3 B](#fig3){ref-type="fig"}). In parallel, we observed the up-regulation of genes linked with several stress-response pathways (e.g., regulation of immune system process, response to DNA damage stimulus, regulation of cell activation, and response to oxidative stress), suggesting that HSCs were sensitive to some of the environmental stresses associated with obesity. Consistent with their cell surface phenotype ([Fig. 1 C](#fig1){ref-type="fig"}), *db* SLAM HSCs were also significantly enriched for the gene signature associated with CD34^--^ SLAM HSCs ([Fig. 3 C](#fig3){ref-type="fig"}; [@bib56]). We then focused our analysis on hematopoietic-relevant transcription factors ([@bib61]) whose expression was affected in obesity. Among the transcriptional factors up-regulated in obesity ([Fig. 3 D](#fig3){ref-type="fig"}), we noted Gfi1, a transcriptional repressor known to regulate HSC quiescence and self-renewal ([@bib33]; [@bib80]). *Gfi1* has been previously described as being highly expressed in the most quiescent CD34^--^ SLAM HSC subset ([@bib15]), a compartment that we found expanded in obesity ([Fig. 1 F](#fig1){ref-type="fig"}). We confirmed by quantitative RT-PCR (qRT--PCR) analyses the higher level of *Gfi1* expression in SLAM HSCs isolated from the *db* and dietary mouse models ([Fig. 3, E and F](#fig3){ref-type="fig"}). Increased *Gfi1* expression in SLAM HSCs was also found in 4-mo-old obese mice with neuron-specific *Lepr* deletion (denoted *Nkx2.1-cre::Lepr^fl/fl^*; [@bib59]) but not in SLAM HSCs isolated from 4-mo-old nonobese mice carrying hematopoietic or BM stromal cell--specific *Lepr* deletions (denoted *Vav1-cre::Lepr^fl/fl^* and *Prx1-cre::Lepr^fl/fl^*, respectively; [Fig. 3 G](#fig3){ref-type="fig"}; [@bib23]; [@bib81]). As such, these results further show that *Gfi1* up-regulation in HSCs is correlated with obesity and not linked to the disruption of the leptin-signaling pathway in the hematopoietic cells or the BM microenvironment. In addition, *Gfi1* up-regulation was not observed in 2-yr-old control mice ([Fig. 3 H](#fig3){ref-type="fig"}), confirming that this feature is not part of an aging gene signature ([@bib60]; [@bib18]).

![**Obesity is associated with up-regulation of *Gfi1* expression in HSCs. (A)** Differential gene signature in SLAM HSCs isolated from in 4-mo-old *Ctrl* and *db* mice. **(B)** GSEA for dysregulated genes in *db* SLAM HSCs. Numbers in parentheses indicate adjusted p-values. **(C)** Enrichment of quiescent CD34^--^ SLAM HSC gene signature ([@bib56]). FDR, false discovery rate; NES, normalized enrichment score. **(D)** Heat map showing examples of differentially expressed transcription factors in *Ctrl* and *db* SLAM HSCs (ordered by *db*/*Ctrl* expression ratio). **(E and F)** qRT-PCR analyses for *Gfi1*, *Bmi1*, and *HoxB4* gene expression in SLAM HSCs isolated from 4-mo-old *db* mice (E) or from 8-mo-old HFD-fed mice (F). Results are expressed as fold change ± SD relative to their respective controls. **(G)** Body weight (left) and qRT-PCR analyses for *Gfi1* expression in SLAM HSCs (right) of *Nkx2.1-cre::Lepr^fl/fl^*, *Vav1-cre::Lepr^fl/fl^*, and *Prx1-cre::Lepr^fl/fl^* mice. Body weights are expressed as means ± SD (*n* = 3--5). qRT-PCR results are expressed as fold change ± SD relative to their respective controls. Student's *t* test; \*\*\*, P ≤ 0.005; \*\*\*\*, P ≤ 0.0005. **(H)** qRT-PCR analyses for *Gfi1* gene expression in old SLAM HSCs (20--24 mo). Results are expressed as fold change ± SD relative to young controls. *n* = 18 pools of 100 cells. Three independent experiments.](JEM_20170690_Fig3){#fig3}

Further analyses in the *db* model showed that *Gfi1* up-regulation in obesity was specific to SLAM HSCs and did not occur in the downstream MPP compartment ([Fig. 4 A](#fig4){ref-type="fig"}). To expand this result, we used a knock-in *Gfi1* reporter mouse carrying a GFP cassette inserted in the endogenous *Gfi1* locus, allowing for the monitoring of the activity of this locus at the single cell level ([@bib78]). We crossed these mice with *Ctrl* or *db* mice to generate two models (hereafter denoted *Ctrl::Gfi1^Gfp/+^* and *db::Gfi1^Gfp/+^)* monitoring the impact of obesity on the *Gfi1* locus. In the *Ctrl::Gfi1^Gfp/+^* model, SLAM HSCs showed a heterogeneous low-to-intermediary level of GFP expression positioned between the nonexpressing megakaryocyte--erythroid progenitors and the high-expressing GMP populations found in the LSK progenitors ([Fig. 4, B and C](#fig4){ref-type="fig"}). *db::Gfi1^Gfp/+^* mice showed similar weight gain to the parental *db* mice (not depicted). Consistent with our gene expression analyses, we found that obesity in this model promotes an increase of GFP expression in SLAM HSCs but not in MPPs ([Fig. 4, B and C](#fig4){ref-type="fig"}). A similar phenotype was found in *Ctrl::Gfi1^Gfp/+^* mice fed with HFD for 8 mo, further confirming the link between obesity and the activity of the *Gfi1* locus in HSCs (Fig. S4, A and B). Consistent with previous research ([@bib16]), we found that *Gfi1* was highly expressed in the most quiescent HSC subset ([Fig. 4 D](#fig4){ref-type="fig"}). However, *Gfi1* up-regulation in obesity was not simply a result of change in SLAM HSC composition, as both GFP detection in reporter mice and gene expression analyses showed that obesity significantly affects *Gfi1* expression in all HSC subsets ([Fig. 4 E](#fig4){ref-type="fig"}). Altogether, these analyses indicate a correlation between obesity and the up-regulation of *Gfi1* in HSCs in three distinct mouse models. They identify two cooccurring effects of obesity: one affecting the architecture of the SLAM HSC compartment (with a relative increase of HSC^CD49+/−^ at the expense of MPP1 cells) and the other affecting the level of *Gfi1* expression in all subsets composing this compartment. As such, our results indicate that *Gfi1* up-regulation is a cell-intrinsic hallmark of the HSCs in obesity and suggest that this molecular feature might contribute to the long-term effect of obesity on the HSC compartment.

![***Gfi1* up-regulation in obesity affects all HSC subsets. (A)** qRT-PCR analyses for *Gfi1* gene expression in SLAM HSCs and MPPs isolated from 4-mo-old *Ctrl* and *db* mice. Results are expressed as fold change ± SD relative to *Ctrl* SLAM HSCs. *n* = 12 pools of 100 cells. **(B)** Representative FACS plots showing GFP fluorescence in SLAM HSCs of 4-mo-old *Ctrl::Gfi1^Gfp/+^* and *db::Gfi1^Gfp/+^* mice. Graph indicates mean percentages ± SD of GFP*^low^* SLAM HSCs. *n* = 4/group. **(C)** Representative FACS plots showing GFP fluorescence in MPPs (left) and in LK progenitors (right) of *Ctrl::Gfi1^Gfp/+^* and *db::Gfi1^Gfp/+^* mice. *n* = 4/group. **(D)** qRT-PCR analyses for *Gfi1* gene expression in HSC subsets isolated from WT mice. Results are expressed as fold change ± SD relative to total SLAM HSCs. *n* = 6 pools of 100 cells. The right panel shows mean RNA-seq expression for *Gfi1* transcripts in dormant long-term label-retaining cell (LRC) HSCs, active non-LRC HSCs, and MPP1 cells (*n* = 3; [@bib16]). **(E)** Representative FACS plots showing GFP fluorescence in HSC subsets of 4-mo-old *Ctrl::Gfi1^Gfp/+^* and *db::Gfi1^Gfp/+^* mice. *n* = 3/group. The right panel shows qRT-PCR analyses for *Gfi1* gene expression in HSC subsets isolated from *db* mice. Results are expressed as fold change ± SD relative to their respective controls. *n* = 6 pools of 100 cells. Student's *t* test (A, B, and E) or one-way ANOVA with Tukey's post hoc test (D); \*, P ≤ 0.05; \*\*\*, P ≤ 0.0005; \*\*\*\*, P ≤ 0.00005. Two independent experiments.](JEM_20170690_Fig4){#fig4}

Obesity has a progressive but long-lasting impact on the HSC compartment {#s06}
------------------------------------------------------------------------

Our results showed that prolonged exposure to obesity affects the HSC compartment and that this effect could be molecularly associated with *Gfi1* up-regulation. To reinforce this link, we next sought to establish the conditions of acquisition for these functional and molecular characteristics. We first examined the HSC compartment at obesity onset in 5-wk-old *db* mice or in 4-mo-old HFD-fed mice ([Fig. 1 A](#fig1){ref-type="fig"}). In both models, we found that the HSPC compartment isolated in the early stage of obesity showed minimal phenotypic disruption ([Fig. 5, A and D](#fig5){ref-type="fig"}). This was associated with a normal SLAM HSC function in competitive transplantation assays ([Fig. 5, B and E](#fig5){ref-type="fig"}). Finally, at obesity onset, we found that SLAM HSCs display levels of *Gfi1* expression indistinguishable from those of controls ([Fig. 5, C and F](#fig5){ref-type="fig"}). Next, we sought to determine whether the effect of obesity was reversible by analyzing the consequences of dietary reversion on HSCs. WT mice were fed with HFD for 10 mo to induce obesity before being switched to CD. This diet reversion dramatically impacted the overall mouse weight, leading toward weight normalization ([Fig. 6 A](#fig6){ref-type="fig"}). Although mouse weight dramatically changed in these conditions, hematological parameters did not reverse even 10 wk after reintroduction of regular chow. As expected for their age (50 wk; [@bib10]), SLAM HSCs in these mice showed increased frequency and low CD34 expression ([Fig. 6 B](#fig6){ref-type="fig"}). Despite this phenotype, we still observed an expansion of the MPP compartment, one of the hallmarks of the LSK compartment in obesity. In addition, SLAM HSCs isolated from the mice after diet reversion maintained a hyperactive phenotype in competitive transplantation assays ([Fig. 6 C](#fig6){ref-type="fig"}). Interestingly, this abnormal function was once again associated with up-regulation of *Gfi1* expression ([Fig. 6 D](#fig6){ref-type="fig"}), suggesting that a high Gfi1 level is a stable cell-intrinsic property of these HSCs. To reinforce this latter result, we analyzed the SLAM HSCs isolated from *db* and HFD conditions and transplanted into nonobese congenic recipient mice. Strikingly, we found that up-regulation of *Gfi1* expression associated with obesity in primary *db* and HFD-fed mice was maintained in HSCs even after these cells were serially transplanted into a nonobese environment for an extended period of time ([Fig. 6 E](#fig6){ref-type="fig"}). Altogether, these results indicate that obesity promotes a progressive change in the HSC compartment during the establishment of obesity but also that this cell-intrinsic effect is long lasting and can persist upon weight loss. These data show that up-regulation of *Gfi1* expression in the HSC compartment, once acquired, is a stable feature that correlated with their aberrant activity upon transplantation.

![**Progressive effect of obesity on the HSC compartment. (A)** Mean percentages ± SD of SLAM HSC/MPPs (left) and CD34^--^ SLAM HSCs (right) in the BM of 5-wk-old *Ctrl* and *db* mice. *n* = 3--4/group. **(B)** PB chimerism in competitive reconstitution assays with SLAM HSCs isolated from *Ctrl* and *db* 5-wk-old mice. Results are expressed as means ± SEM. *n* = 4/group. **(C)** qRT-PCR analyses for *Gfi1* in SLAM HSCs isolated from 5-wk-old *db* mice. Results are expressed as fold change ± SD relative to *Ctrl* SLAM HSCs. *n* = 12 pools of 100 cells. **(D)** Mean percentages ± SD of SLAM HSC/MPPs (left) and CD34^--^ SLAM HSCs (right) in the BM of 4-mo-old mice fed with HFD. *n* = 8/group. Student's *t* test; \*, P ≤ 0.05. **(E)** PB chimerism in competitive reconstitution assays with SLAM HSCs isolated from 4-mo-old mice fed with HFD. Results are expressed as means ± SEM. *n* = 4/group. **(F)** qRT-PCR analyses for *Gfi1* in SLAM HSCs isolated from 4-mo-old mice fed with HFD. Results are expressed as fold change ± SD relative to CD SLAM HSCs. *n* = 12 pools of 100 cells. Two independent experiments.](JEM_20170690_Fig5){#fig5}

![**Long-lasting effect of obesity on the HSC compartment. (A)** Kinetics of weight variation after diet change. Data are represented as means ± SD. *n* = 4/group. **(B)** Mean percentages ± SD of SLAM HSC/MPPs (left) and CD34^--^ SLAM HSCs (right) in the BM of mice constantly fed with CD or experiencing diet change. *n* = 4/group. **(C)** PB chimerism in competitive reconstitution assays with SLAM HSCs isolated from mice constantly fed with CD or experiencing diet change. The right graph shows myeloid and lymphoid PB chimerism 20 wk after transplantation. Results are expressed as means ± SEM. *n* = 11--12/group. **(D)** qRT-PCR analyses for *Gfi1* gene expression in SLAM HSCs isolated from mice experiencing diet change. Results are expressed as fold change ± SD relative to controls. *n* = 16 pools of 100 cells. **(E)** qRT-PCR analyses for *Gfi1*, *Bmi1*, and *HoxB4* genes in *db* (left) and HFD SLAM HSCs (right) after serial transplantations. Results are expressed as fold change ± SD relative to their respective controls. *n* = 12 pools of 100 cells. Student's *t* test; \*, P ≤ 0.05; \*\*\*, P ≤ 0.005; \*\*\*\*, P ≤ 0.0005. Two independent experiments.](JEM_20170690_Fig6){#fig6}

*Gfi1* up-regulation mediates HSC-functional dysregulations in obesity {#s07}
----------------------------------------------------------------------

To determine whether *Gfi1* up-regulation directly affects the function of HSCs in obesity, we used a loss-of-function approach with the aforementioned *Ctrl::Gfi1^Gfp/+^* and *db::Gfi1^Gfp/+^* reporter mice in which GFP insertion leads to the disruption of one *Gfi1* allele ([@bib78]). In nonobese conditions, we found that *Gfi1* haploinsufficiency led to reduced *Gfi1* expression in SLAM HSCs, a result consistent with published studies in other cellular contexts ([Fig. 7, A and B](#fig7){ref-type="fig"}; [@bib78]; [@bib29]; [@bib34]). Haploinsufficiency in the obese condition blunted the *Gfi1* up-regulation and led to a normalization of *Gfi1* expression in the overall SLAM HSC compartment and in the subsets that compose this compartment. Modulation of *Gfi1* expression in obesity normalized the size of the MPP compartment but failed to affect the obesity-associated phenotype in SLAM HSCs ([Fig. 7 C](#fig7){ref-type="fig"}). In contrast, we observed that *Gfi1* haploinsufficiency affects SLAM HSC cell cycle status by reducing quiescence both in the *Ctrl* and *db* background ([Fig. 7 D](#fig7){ref-type="fig"}). Particularly, *Gfi1* haploinsufficiency led to a normalization of the SLAM HSC cell cycle status in obesity. Alteration of *Gfi1* gene dosage also correlated with the normalization of the expression of the cell cycle regulator *Cdkn1a* (*p21*) but not *Cdkn1c* (*p57*; Fig. S5). Using competitive transplantation assays (as shown in [Fig. 2 A](#fig2){ref-type="fig"}), we then assessed the impact of *Gfi1* haploinsufficiency on the HSC function ([Fig. 7 E](#fig7){ref-type="fig"}). *Ctrl::Gfi1^Gfp/+^* SLAM HSCs displayed a significantly reduced reconstitution ability compared with *Ctrl* SLAM HSCs in both primary and secondary transplantation. In obesity, *Gfi1* haploinsufficiency also affected the SLAM HSC activity, leading to the normalization of their reconstitution capability. Notably, we found that *Gfi1* haploinsufficiency reversed the hyperactive phenotype of the *db* SLAM HSCs in primary transplantation as well as the associated functional exhaustion detected in secondary transplantation. Altogether, these results show that *Gfi1* haploinsufficiency does not affect the phenotypic characteristics of the *db* SLAM HSC compartment but normalizes its function (as measured by cell cycle status and reconstitution capability). Therefore, these results indicate that a tight control of *Gfi1* expression is critical to HSC function, particularly during stress, and show that *Gfi1* is one of the key determinants of HSC function in obesity.

![**Gfi1 controls HSC fate in obesity. (A)** qRT-PCR analyses for *Gfi1* gene expression in SLAM HSCs isolated from 4-mo-old *db*, *Ctrl::Gfi1^Gfp/+^*, and *db::Gfi1^Gfp+^* mice. Results are expressed as fold change ± SD relative to total *Ctrl* SLAM HSCs. *n* = 6--12 pools of 100 cells. Student's *t* test; \*\*, P ≤ 0.01; \*\*\*\*, P ≤ 0.0005. Three independent experiments. **(B)** qRT-PCR analyses for *Gfi1* gene expression in HSC subsets isolated from 4-mo-old *Ctrl*, *Ctrl::Gfi1^Gfp/+^*, and *db::Gfi1^Gfp/+^* mice. Results are expressed as fold change ± SD relative to total *Ctrl* SLAM HSCs. *n* = 6--12 pools of 100 cells. Two-way ANOVA with Tukey's post hoc test; \*, P ≤ 0.05; \*\*, P ≤ 0.005; \*\*\*\*, P ≤ 0.0001. Two independent experiments. **(C)** Mean percentages ± SD of SLAM HSC/MPPs (left) and HSC subsets (right) in the BM of 4-mo-old *Ctrl*, *db*, *Ctrl::Gfi1^Gfp/+^*, and *db::Gfi1^Gfp+^* mice. *n* = 8--18. **(D)** Representative FACS plots (left) and mean percentages ± SD (right) showing SLAM HSC distribution in cell cycle phases. *n* = 4--6 mice/group. One-way ANOVA with Tukey's post hoc test; \*, P ≤ 0.05; \*\*, P ≤ 0.005; \*\*\*, P ≤ 0.001. Two independent experiments. **(E)** PB chimerism in primary (left) and secondary (right) competitive reconstitution assays using SLAM HSCs isolated from *Gfi1^Gfp/+^* and *db* compound mice. Results are expressed as means ± SEM. *n* = 4--8/group. Student's *t* test; *Ctrl* vs. *db*: \*, P ≤ 0.05; \*\*, P ≤ 0.005; *Ctrl* vs. *Ctrl::Gfi1^Gfp/+^*: °, P ≤ 0.05; °°, P ≤ 0.05; *db* vs. *db::Gfi1^Gfp/+^*: ^\#^, P ≤ 0.05; ^\#\#^, P ≤ 0.005; ^\#\#\#^, P ≤ 0.0005. Two independent experiments.](JEM_20170690_Fig7){#fig7}

Oxidative stress is a driver for HSC dysregulation in obesity {#s08}
-------------------------------------------------------------

Although *Gfi1* haploinsufficiency normalizes the *db* HSC functions, we found that it also negatively impacts the *Ctrl* HSCs. To rule out a potential nonspecific effect of *Gfi1* haploinsufficiency, we investigated the upstream mechanisms of *Gfi1* regulation in obesity. We reasoned that the initial activation of the *Gfi1* locus could be driven by cellular stresses associated with obesity. We found that SLAM HSCs isolated from 4-mo-old *db* mice displayed a significantly increased level of reactive oxygen species (ROS; [Fig. 8 A](#fig8){ref-type="fig"}). As expected, the treatment of *db* mice with the antioxidant *N*-acetyl cysteine (NAC; 60 mM in drinking water administered ad libitum for 4 wk) during the establishment of the obese phenotype (3--4 mo of age) led to a normalization of the ROS level ([Fig. 8 B](#fig8){ref-type="fig"}). NAC treatment during this limited period did not affect the expansion of the *db* MPP compartment or the phenotype of the *db* SLAM HSCs ([Fig. 8 C](#fig8){ref-type="fig"}). In contrast, removal of this oxidative stress led to the normalization of *Gfi1* expression in *db* SLAM HSCs ([Fig. 8 D](#fig8){ref-type="fig"}), suggesting that *Gfi1* expression could be regulated by oxidative stress in HSCs. Consistent with this idea, we found that in vivo induction of ROS in WT mice using buthionine sulfoximine (BSO) treatment ([@bib65]) led to the up-regulation of *Gfi1* expression in SLAM HSCs but not in the downstream MPP compartment ([Fig. 8 E](#fig8){ref-type="fig"}). A similar effect was found when purified SLAM HSCs were treated in vitro with BSO ([@bib44]; [@bib36]), indicating a direct and dose-dependent effect of ROS on *Gfi1* expression in HSCs ([Fig. 8 F](#fig8){ref-type="fig"}). Finally, we found that normalization of *Gfi1* expression in obesity after NAC treatment fully rescues the HSC hyperactive activity upon transplantation ([Fig. 8 G](#fig8){ref-type="fig"}). Importantly, NAC treatment did not disrupt *Gfi1* expression in *Ctrl* HSCs and did not affect their function upon transplantation. Altogether, these results fully mimic those obtained with *Gfi1* haploinsufficient mice and therefore independently confirm the link between *Gfi1* up-regulation and HSCs' aberrant function in obesity. These results indicate that oxidative stress is a key contributor to the initial dysregulation of the *Gfi1* locus during the establishment of obesity and identify *Gfi1* as an oxidative stress-response gene in HSCs.

![**Oxidative stress is a key driver of HSC dysregulation in obesity. (A)** Representative FACS plots (left) and mean fluorescence intensity (MFI) ± SD (right) showing ROS level detected by 2',7'--dichlorofluorescin diacetate (DCFDA) staining in SLAM HSCs isolated from 4-mo-old *Ctrl* and *db* mice. *n* = 3/group. Student's *t* test; \*, P ≤ 0.05. Two independent experiments. **(B)** Representative FACS plots (left) and mean fluorescence intensity ± SD (right) showing ROS level in SLAM HSCs isolated from NAC-treated *Ctrl* and *db* mice. *n* = 4--7/group. **(C)** Mean percentages ± SD of SLAM HSC/MPPs (left) and CD34^--^ SLAM HSCs (right) in the BM isolated from NAC-treated *Ctrl* and *db* mice. *n* = 5/group. **(D)** qRT-PCR analyses for *Gfi1* gene expression in SLAM HSCs isolated from NAC-treated *Ctrl* and *db* mice. Results are expressed as fold change ± SD relative to vehicle-treated *Ctrl* SLAM HSCs. *n* = 6--12 pools of 100 cells. One-way ANOVA with Tukey\'s post hoc test; \*, P ≤ 0.05; \*\*, P ≤ 0.005. Two independent experiments. **(E)** Representative FACS plots (left) and qRT-PCR analyses (right) showing ROS level and *Gfi1* gene expression in SLAM HSCs isolated from BSO-treated WT mice. Results are expressed as fold change ± SD relative to vehicle-treated mice. *n* = 6--12 pools of 100 cells. Student's *t* test; \*, P ≤ 0.05. Two independent experiments. **(F)** Representative FACS plots (left) and qRT-PCR analyses (right) showing ROS level and *Gfi1* gene expression in SLAM HSCs cultured for 48 h in presence of BSO. Results are expressed as fold change ± SD relative to vehicle-treated mice. *n* = 5--9 pools of 100 cells. One-way ANOVA with Dunnett's post hoc test; \*, P ≤ 0.05; \*\*\*, P = 0.0005. Three independent experiments. **(G)** PB chimerism in competitive reconstitution assays using SLAM HSCs isolated from vehicle- or NAC-treated *Ctrl* and *db* mice. The right graph shows myeloid and lymphoid PB chimerism 20 wk after transplantation. Results are expressed as means ± SEM. *n* = 7/group. Student's *t* test; *Ctrl* + *Veh.* vs. *db* + *Veh.*: \*\*, P ≤ 0.005; \*\*\*, P ≤ 0.0005; \*\*\*\*, P ≤ 0.00005; *db* + *Veh.* vs. *db* + *NAC*: ^\#^, P ≤ 0.01; ^\#\#^, P ≤ 0.005. Two independent experiments.](JEM_20170690_Fig8){#fig8}

Discussion {#s09}
==========

Using independent mouse models, our results demonstrate that obesity has a durable effect on the HSC compartment. Although HSCs in obesity only display limited phenotypic and functional perturbations at steady-state, they show an exacerbated proliferative response to hematopoietic stresses along with intermediate-term hematopoietic reconstitution capability. Mechanistically, we found that this aberrant HSC activity is linked to the acquisition of specific molecular features, particularly the up-regulation of *Gfi1* expression. We show that these molecular and functional abnormal HSC features are progressively acquired during the establishment of obesity but remain stable even when the stresses associated with obesity are relieved after weight loss or transplantation into a normal recipient. Finally, we demonstrate that Gfi1 is one of the key regulators of HSC fate in obesity in response to the abnormal oxidative environment associated with this condition. In sum, obesity produces sustained changes in HSC function and phenotype that are mirrored at the molecular level by durable elevation in *Gfi1* expression, which is genetically linked to the changes in HSC function but not phenotype.

Although obesity and aging share many common immunological, metabolic, and hormonal characteristics ([@bib2]; [@bib3]), our results draw a sharp contrast in the impact of these two conditions on the HSC compartment. Although aging is associated with the accumulation of a myeloid-biased CD150^high^ HSC population with a low capacity for hematopoietic reconstitution ([@bib60]; [@bib10]), none of these characteristics were found in obesity. In contrast, our results show that obesity promotes changes in the cellular architecture of the HSC compartment and lead to an exacerbated proliferative response upon transplantation. Consistent with this idea, the HSC gene expression profile associated with obesity is different from the gene signatures previously associated with aging ([@bib60]; [@bib18]). Notably, we identify the up-regulation of *Gfi1* as a specific HSC characteristic in obesity that it is not found in aging. As such, our results indicate that the effect of obesity on the HSC compartment is distinct from premature aging. Similarly, our data indicate that the effects of obesity on the HSC compartment do not mimic the effects of acute and chronic inflammatory conditions, which are associated with HSC cell cycle activation and rapid functional exhaustion ([@bib25]; [@bib9]; [@bib24]). In this study, we show that HSCs in obesity acquired an immature CD34^neg^ phenotype and remain quiescent. Although inflammatory signals present in obesity have been shown to impact the downstream GMP compartment ([@bib50]), these results suggest that HSCs could be refractory to the low-grade inflammation associated with obesity. We can speculate that this property is caused by a higher threshold of activation or the presence of cell-intrinsic protective mechanisms activated in obesity (see below). In any case, our results indicate that the effect of obesity on the HSC compartment cannot be solely reduced to its systemic inflammatory components. In contrast, they establish obesity as a singular chronic pathophysiological state. The conditions that are actually responsible for the dysregulation of the HSC compartment in obesity remain to be fully established. Of note, the phenotype, the quiescence status, and the reconstitution pattern described for HSCs in obesity are reminiscent of the characteristics found in HSCs isolated from BM adipocyte-rich regions ([@bib51]). This suggests that changes in the adipose tissues in the BM could be among the major drivers of the HSC phenotype in obesity ([@bib4]).

Our work describes a novel ROS--*Gfi1* pathway linking oxidative stress response and mechanisms controlling HSC fate in obesity. Although obesity is associated with an increased level of intracellular ROS in HSCs, we found that the functional consequences of this phenomenon are mild in obesity compared with previous research, which describes ROS inducing a rapid HSC exhaustion through induction of the p38 mitogen-activated protein kinase ([@bib36]). This could suggest that the level of intracellular ROS present in obesity may not be sufficient to fully activate this pathway. Alternatively, it could also indicate that the progressive acquisition of the oxidative stress during the establishment of obesity leads to specific adaptive response mechanisms in HSCs. In this study, we show that the oxidative stress associated with obesity directly impacts on *Gfi1* expression in HSCs but not in downstream MPPs. *Gfi1* expression is tightly controlled in HSCs and is a key regulator of HSC quiescence as *Gfi1*-knockout HSCs fail to remain quiescent and undergo rapid functional exhaustion ([@bib33]; [@bib80]). We found that *Gfi1* haploinsufficiency also reduces HSC quiescence and limits their hematopoietic reconstitution ability upon transplantation. Conversely, we found that a nominally modest two- to threefold up-regulation of *Gfi1* suffices to affect HSC function. As such, Gfi1 acts as a rheostat able to fine-tune the properties of the HSC compartment. As others, we found that *Gfi1* expression level correlates with *Cdkn1a* (p21) expression in HSCs ([@bib33]; [@bib80]). However, it remains unclear whether p21 expression is directly linked to Gfi1 activity and actually contributes to the HSC properties ([@bib45]). In obesity, we show that Gfi1 plays a dual role contributing to reinforce HSC quiescence at steady state while also affecting their response to stress assayed in serial transplantations. Importantly, modulation of *Gfi1* expression through gene dosage or antioxidant treatment is effective in restoring normal HSC functional properties. These results demonstrate that the ROS--Gfi1 axis controls the fitness of the overall HSC compartment in obesity. Consistent with this point, *Gfi1* modulation during the establishment of the obese phenotype in the haploinsufficient model also prevents the expansion of the downstream MPP compartments. In contrast, *Gfi1* modulation fails to reverse the HSC phenotypic features associated with obesity and, notably, the change in the proportion of the different HSC subsets. This disconnect between HSC phenotype and function suggests that other factors are controlling the transition between these different subsets but that *Gfi1* up-regulation is dominant in modulating the overall activity of these subsets. Further studies will be needed to determine whether the ROS--Gfi1 axis has a differential impact on each of the HSC subsets. Altogether, our work highlights the unique importance of Gfi1 in HSC biology and the need to decipher its downstream regulatory programs in this compartment. It also indicates that deciphering the molecular pathway linking oxidative stress response to *Gfi*1 expression could be key to understanding the dysregulation of HSC functions in chronic stress conditions.

Finally, our work establishes that some of the alterations in the HSC compartment were long lasting after weight loss or transplantation into a normal environment. Thus, the status of the HSCs during established obesity dramatically differs from the reversible HSC activation observed upon acute BM injury or granulocyte colony-stimulating factor (G-CSF) treatment ([@bib75]). Molecularly, these changes in the HSC compartment were associated with and supported by the activation of the *Gfi1* locus. Although progressively acquired and initially dependent on obesity-induced ROS level during obesity establishment, *Gfi1* up-regulation persists even as HSCs are transferred into a normal environment, suggesting that obesity also promotes stable alterations in the *Gfi1* locus. These results are reminiscent of the chromatin accessibility and epigenetic changes induced by HFD in liver tissue, and they suggest that epigenetic alterations could also contribute to the change in function of the HSC compartment in obesity ([@bib42], [@bib43]). Altogether, our results indicate that obesity is associated with an alteration of the regulatory programs in the different HSC pools along with ROS accumulation and dysregulation of the stress response. Interestingly, the same alterations have been linked to age-related hematological pathologies ([@bib3]). In the clinic, obesity is associated with multiple hematological disorders ranging from immunodeficiency ([@bib26]; [@bib35]) to increased susceptibility to hematological malignancies ([@bib53]; [@bib57]; [@bib54]; [@bib13]). Future studies will need to address the relevance of the HSC alterations on the fitness of the hematopoietic system in obese patients and their potential contribution to the development of hematopoietic pathologies.

Materials and methods {#s10}
=====================

Mice {#s11}
----

*WT*, *Lepr^db/db^(db)*, *LepR^fl/fl^*, *Vav-cre*, *Nkx2-1-cre*, *Prx1-cre*, and *Gfi1^Gfp/+^* mice (all in C57BL/6 background) were purchased from The Jackson Laboratory and housed at the Association for Assessment and Accreditation of Laboratory Animal Care International--accredited animal facility of the Cincinnati Children's Hospital Medical Center. Nonmutant littermates were used as controls for each experiment. For the dietary model of obesity, WT C57BL/6 mice were maintained in control diet with 13 Kcal% fat (5010; Lab Diets) or switched to an HFD with 60 Kcal% fat (D12492; Research Diet, Inc.) at 5 wk of age for a duration of 8 mo. 8--12-wk-old C57BL/6 congenic mice (*Ptprc^a^ Pepc^b^/BoyJ*) were used as recipients for cell transplantation experiments. All animal experiments were approved by the Cincinnati Children's Institutional Animal Care and Use Committee.

Flow cytometry {#s12}
--------------

Cell surface staining and HSC isolation procedures were performed as described previously ([@bib58]). In brief, BM cells were obtained by crushing long bones and hips, treating with ACK (150 mM NH~4~Cl and 10 mM KHCO~3~) to lyse red blood cells, and purifying the cells by Ficoll separation (Histopaque-1119; Sigma-Aldrich). Unfractionated or autoMACS (Miltenyi Biotec)-enriched c-kit^+^ cells were stained with unconjugated rat lineage-specific antibodies (Lin, Ter-119, Mac1, Gr-1, B220, CD5, CD3, CD4, CD8, and CD127), followed by staining with goat anti--rat PE-Cy5 secondary antibody. Cells were then stained with c-kit--APC-eFluor780, Sca1-PB, CD48--Alexa Fluor 647, CD150-PE, CD34-FITC, CD49b-biotin/streptavidin-PE-Cy7, and FcγR-PerCP-eFluor710 antibodies. Blood- and BM-differentiated cells were stained with Ter119-PE-Cy5, CD3-APC, B220-APC-eFluor780, Mac1-PE-Cy7, and Gr-1-PB antibodies. B progenitors were stained with B220-BV421 and IgM-APC-eFluor780 antibodies. CD45.1--Alexa Fluor 700 and CD45.1-FITC antibodies were included for blood chimerism analysis and isolation of donor-derived HSCs after transplantation. All antibodies used in this study can be found in Table S1. Stained cells were resuspended in Hank's buffered salt solution with 2% heat-inactivated FBS and 1 µg/ml propidium iodide for dead cell exclusion. For cell cycle status, surface-stained cells (Lin-PeCy5, c-kit--APC-eFluor780, Sca1-PE-Cy7, CD48-PercP-cy5.5, and CD150-APC were incubated at 37°C for 30 min with Hoechst 33342 (5 µg/ml; Molecular Probes) in the presence of verapamil (50 µg/ml; Sigma-Aldrich) and pyronin Y (0.05 µg/ml; Sigma-Aldrich). For Hoechst 33342/Ki67 staining, surface-stained cells were fixed and permeabilized using a Cytofix/Cytoperm kit (BD) before staining with a PE-conjugated anti-Ki67 antibody (BioLegend) and Hoechst 33342 (5 µg/ml). For measuring intracellular ROS levels, surface-stained cells were incubated with 1 µM 2,7-dichlorofluorescin diacetate (Sigma-Aldrich) for 15 min in a 37°C water bath before flow cytometry analysis. Cell sorting and analysis were performed on a FACS ARIAII and a FACS LSRII or LSRFortessa (BD). Data analysis was performed using FlowJo software (BD).

In vivo assays {#s13}
--------------

For competitive transplantation assays, 8--12-wk-old CD45.1 C57BL/6 congenic recipient mice were lethally irradiated (11 Gy delivered in split doses 3 h apart) and retroorbitally injected with 250 or 500 purified SLAM HSCs (CD45.2^+^) together with 500,000 or 300,000 *BoyJ* whole BM cells (CD45.1^+^) as competitors. Transplanted mice were kept on antibiotic-containing water (neomycin sulfate/polymyxin B sulfate; Sigma-Aldrich) for 4 wk and analyzed for donor-derived chimerism by monthly bleeding. Peripheral blood was collected by retroorbital bleeding, treated with ACK, and stained with specific antibodies for flow cytometry analysis. For ROS inhibition, *db* and littermate control mice were given 10 mg/ml of NAC (Sigma-Aldrich) in drinking water that was changed daily for 4 wk. For in vivo glutathione depletion and induction of intracellular ROS, mice were intraperitoneally injected for 5 d with the glutathione synthesis inhibitor BSO (800 mg/kg daily; Sigma-Aldrich) or vehicle (PBS). Blood and BM phenotypes were analyzed, and HSCs were purified for molecular and functional analysis at the end of treatment.

In vitro assays {#s14}
---------------

Purified SLAM HSCs were cultured in StemPro-34 media (Invitrogen) complemented by glutamine and cytokines (stem cell factor, 20 ng/ml; thrombopoietin, 20 ng/ml). For division-tracking experiments, cells were sorted directly into 60-well terasaki plates (one cell per well) and visually monitored at the indicated time points to assess the kinetics of the first division. For in vitro glutathione depletion and induction of intracellular ROS, purified SLAM HSCs were cultured in 96-well plates (5,000--10,000 per well) in the presence of indicated concentration of BSO (50--200 µM). After 48 h in culture, cells were analyzed for ROS level and gene expression.

RNA sequencing {#s15}
--------------

20,000 SLAM HSCs were isolated from *db* and littermate control mice by FACS sorting directly into TRIzol (Invitrogen). After chloroform extraction, total RNA was purified using a RNeasy microKit column system (QIAGEN). Three independent replicates were isolated in parallel to ensure reproducibility and allow statistical analysis. RNA quality was controlled using a Bioanalyzer (Agilent Technologies) before being processed for retrotranscription, linear amplification, and cDNA library generation. The whole transcriptome was amplified using the SMARTer Ultra Low RNA kit for Illumina Sequencing (Takara Bio Inc.). cDNA libraries were prepared using Nextera XT DNA Sample preparation reagents. Fragmented and tagged libraries were pooled and examined using a high-sensitivity DNA chip (Agilent Technologies). Libraries were sequenced on a HiSeq 2500 platform (Illumina) using the pair-end 75-bp sequencing strategy.

Bioinformatics analyses {#s16}
-----------------------

RNA-Seq data were aligned and quantified (transcript per million estimates) using the software BowTie2 and RNA-seq by expectation maximization with the mm10 UCSC transcriptome reference. All differentially expressed genes were identified based on an empirical Bayes-moderated *t* test p-value \<0.05. For all heatmaps, log~2~-transformed transcripts per million values were normalized to the median expression of each gene across all compared cells/samples. GSEAs were performed using AltAnalyze (GO-Elite algorithm) using gene sets from the embedded Gene Ontology, ImmGen, and Pathway Commons database ([@bib79]). Comparative analyses with previously published signatures were performed with differentially expressed genes using GSEA v2.0 software ([@bib67]). The GEO accession number for RNA sequencing data was [GSE90725](GSE90725).

qRT-PCR array {#s17}
-------------

qRT-PCR arrays were performed in multiplex assays as previously described ([@bib58]). For each experiment, pools of 100 cells were directly sorted into 5 µl of resuspension buffer from Cellsdirect One-Step qRT-PCR kits (Invitrogen). Samples were used for gene-specific based reverse transcription (SuperScript III; Thermo Fisher Scientific) and preamplified for 18 cycles with Platinum Taq DNA polymerase in presence of multiplex primer mix (50 nM each). Resulting cDNA products were diluted fivefold in TE buffer (10 mM Tris and 0.1 mM EDTA, pH 8.0) and analyzed on a 7900 HT Fast Real-Time PCR System (Applied Biosystems) using gene-specific primers and SYBR green reagents (Applied Biosystems). Each measurement was performed in duplicate with a β-actin (*Actb*) housekeeping gene used for normalization. Primers used for preamplification and quantitative measurement were intron-spanning and validated on serial dilution of total mouse cDNA to ensure linear amplification and PCR specificity. Sequences for qRT-PCR primers can be found in Table S2. Results were validated by classical qRT-PCR using total RNA isolated from ∼0.5--2 × 10^4^ cells. RNA was treated with DNase I and reverse-transcribed using SuperScript III kit and random hexamers (Invitrogen). cDNA equivalent of 200 cells per reaction were used for quantitative PCR assays with SYBR green reagents.

Statistics {#s18}
----------

All results are expressed as means with error bars reflecting SD or SEM as indicated. *n* represents the number of animals per experiment. Differences between two groups were assessed using unpaired two-tailed Student's *t* tests. Data involving more than two groups were assessed by one-way or two-way ANOVAs with Tukey's or Dunnett's post hoc tests.

Online supplemental material {#s19}
----------------------------

Fig. S1 shows hematopoietic disruption associated with established obesity in the dietary (HFD) mouse model. Fig. S2 documents gene expression and kinetics of division of different HSC subsets. Fig. S3 shows the validation of the HSC functional dysregulation in dietary mouse model. Fig. S4 shows the activity of the Gfi1 locus in *Ctrl::Gfi1^Gfp/+^* knock-in mice fed with HFD for 8 mo. Fig. S5 shows the effect of *Gfi1* gene dosage on the expression of *Cdkn1a* and *Cdkn1c*. Tables S1 and S2 list the antibodies and the primer sequences used for flow cytometry and qRT-PCR analyses, respectively. Table S3 provides source data for the heatmap of gene expression and GSEAs generated from 4 mo *Ctrl* and *db* HSCs.
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